APOC2 Genotype

If you have ever been told your triglycerides are unusually high without a clear lifestyle reason, or if pancreatitis runs in your family, this test asks a specific question: do you carry a rare change in the APOC2 (apolipoprotein C-II) gene that disrupts how your body clears fat from the blood? The APOC2 gene gives instructions for a small helper protein that activates the enzyme responsible for breaking down triglyceride-rich particles after meals.

Most people will never carry a meaningful APOC2 variant. But for the few who do, the consequences can be severe: triglycerides so high they trigger recurrent pancreatitis, sometimes life-threatening, that no standard lipid panel can fully explain. Knowing your genotype settles the question and changes how you and your family approach prevention.

What This Gene Actually Does

APOC2 makes apolipoprotein C-II, a small protein that rides on fat-carrying particles in your blood. Its job is to switch on lipoprotein lipase, the enzyme that breaks down triglycerides so your body can use or store the fat. Without functional apoC-II, the lipase cannot do its work efficiently, and triglyceride-rich particles pile up in the bloodstream.

This test reads the DNA sequence at the APOC2 gene to look for variants that disrupt this protein. The genotype you carry was set at conception and does not change over your lifetime. What it tells you is not what your triglycerides are doing today, but what your inherited capacity to clear them looks like.

Severe Hypertriglyceridemia and Pancreatitis Risk

The strongest, best-documented consequence of disabling APOC2 variants is familial chylomicronemia syndrome (FCS), a condition where triglycerides reach extreme levels and pancreatitis becomes a recurring threat. In a documented case, a person carrying a homozygous missense variant called R72T had undetectable apoC-II in plasma, severe hypertriglyceridemia, and recurrent pancreatitis. A separate Chinese case identified a different homozygous variant producing the same picture: very low apoC-II, very high triglycerides, and pancreatitis.

APOC2 variants are an uncommon cause of FCS overall, accounting for roughly 1 to 5 percent of monogenic cases, with most caused by variants in a related gene called LPL. But when APOC2 is the cause, the clinical picture is just as severe, and the treatment approach differs. Knowing the specific gene involved changes which therapies make sense.

In a study of 563 people with severe hypertriglyceridemia, only about 1% carried two damaging copies of any FCS gene. Most cases were polygenic, meaning many small variants added up rather than one large disruption. APOC2 testing matters most when triglycerides are extreme, pancreatitis has happened, and standard explanations have been ruled out.

Kidney Disease From APOC2 Amyloidosis

A separate group of APOC2 variants causes something different: a rare hereditary form of kidney amyloidosis, where abnormal apoC-II protein accumulates in kidney tissue and damages it. Variants including p.Lys41Thr and K19T have been identified in older adults presenting with heavy protein in the urine and progressive kidney decline, sometimes without elevated triglycerides at all.

In a case series of 25 people with renal apoC-II amyloidosis, kidney failure was common, and the condition predominantly affected elderly individuals. This is a distinct disease from FCS and involves different variants in the same gene. If you carry one of these amyloid-associated variants, kidney monitoring becomes a long-term priority.

Common Variants and Heart Disease

Beyond the rare disease-causing variants, common variation in the APOC2 region has been linked to subtler effects on blood lipids and heart risk. In a study of UK men, carriers of a common variant called rs5127 had lower coronary heart disease risk than non-carriers in some analyses, though the authors noted these findings need confirmation. A separate sequencing study across the APOE-C1-C4-C2 gene cluster found numerous sequence variants influencing lipid traits.

These common-variant effects are modest compared to the rare disease-causing mutations. Whether your specific genotype panel reports them depends on which variants the assay covers.

Reconciling the Different Risk Patterns

APOC2 is not a simple "good number, bad number" gene. The same gene can produce three very different problems: complete loss of function causes runaway triglycerides and pancreatitis, certain missense changes cause kidney amyloid disease without any lipid abnormality, and common variants in the region nudge lipid levels and heart risk in either direction. The variant matters more than the gene itself. Two people with "a variant in APOC2" can face entirely different risks depending on which specific change they carry.

Why a One-Time Test Has Lifelong Value

This is a genetic test, so the result does not change. You take it once, and the answer is yours for life. There is no need to retest unless the lab calls a result of uncertain meaning, or unless a more comprehensive method is used later to confirm an unexpected finding.

The value of the test is not in the result itself but in what you do with it for decades afterward. If you carry a disease-causing variant, your triglyceride monitoring cadence changes. Pancreatitis prevention becomes a priority. Family members, especially siblings and children, become candidates for cascade testing. If you carry a kidney-amyloid variant, regular urine protein and kidney function checks become a long-term part of your care.

When Results Can Be Misleading

• Panel coverage limits: the test only detects the specific variants it was designed to find. A negative result does not rule out other rare or novel APOC2 variants that the panel was not built to detect.
• Ancestry differences: known APOC2 disease variants have been described in people of various backgrounds, including European and Chinese populations. The interpretation of a finding can depend on whether that variant has been studied in people of your ancestry.
• Variants of uncertain significance: the lab may report a change in APOC2 whose clinical meaning is unknown. This is not a diagnosis of disease, and it is not a clean bill of health. It is a holding pattern until more evidence accumulates.
• Clinical-grade versus consumer reports: if you have seen a result for APOC2 from a direct-to-consumer service, that finding usually needs to be confirmed by a clinical-grade laboratory before being acted on.

Decision Pathway for an Unexpected Result

If your test identifies a disease-causing APOC2 variant, the next steps depend on which kind. For a variant associated with familial chylomicronemia, the workup should include a fasting lipid panel with triglycerides, measurement of apoC-II protein, and a conversation with a lipidologist about pancreatitis prevention. Cascade testing for first-degree relatives, including children and siblings, becomes important because the same variant in close family members can be life-threatening if undetected.

For a variant associated with kidney amyloidosis, the pathway shifts to nephrology. A urine albumin-to-creatinine ratio, serum creatinine, cystatin C, and a discussion with a kidney specialist about long-term monitoring are appropriate. A genetic counselor can help interpret a variant of uncertain significance and decide whether further sequencing is warranted.

If the test is negative for known disease-causing variants but you or your family have a history of unexplained severe hypertriglyceridemia, broader sequencing of related genes (LPL, APOA5, LMF1, GPIHBP1) may be the next step. APOC2 is just one piece of a small panel that explains rare lipid disorders.